Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
InFo Hämatologie + Onkologie
Erschienen in: InFo Hämatologie + Onkologie 7-8/2022

28.07.2022 | Pleuramesotheliome | Zertifizierte Fortbildung

Brustfellkrebs

Epidemiologie, Diagnostik und Therapie des Pleuramesothelioms

verfasst von: Dr. med. Dominik Valentin Flury, Prof. Dr. med. Gregor J. Kocher

Erschienen in: InFo Hämatologie + Onkologie | Ausgabe 7-8/2022

Einloggen, um Zugang zu erhalten

Auszug

Das Pleuramesotheliom ist eine seltene Erkrankung des Brust- und Lungenfells mit schlechter Prognose. Lesen Sie in der folgenden Übersicht, wann an diese Erkrankung gedacht werden soll, wann Abklärungsbedarf besteht und wie, basierend auf den aktuellen Guidelines, Diagnostik-, Staging- sowie Behandlungsstrategien aussehen. …
Literatur
1.
Alpert N et al. Epidemiology of mesothelioma in the 21 st century in Europe and the United States, 40 years after restricted/banned asbestos use. Transl Lung Cancer Res. 2020;9(Suppl 1):S28-S38
2.
WHO Classification of Tumours Editorial Board. Thoracic tumours. Lyon (France): International Agency for Research on Cancer; 2021:200-2019
3.
Popat S et al. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(*). Ann Oncol. 2022;33(2):129-42
4.
Kazan-Allen L. Current Asbestos Bans; www.ibasecretariat.org/alpha_ban_list.php abgerufen am 4. Juli 2022
5.
Røe OD, Stella GM. Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic. Eur Respir Rev. 2015;24(135):115-31
6.
Odgerel CO et al. Estimation of the global burden of mesothelioma deaths from incomplete national mortality data. Occup Environ Med. 2017;74(12):851-8
7.
Bianchi C, Bianchi T. Global mesothelioma epidemic: Trend and features. Indian J Occup Environ Med. 2014;18(2):82-8
8.
Delgermaa V et al. Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ. 2011;89(10):716-24, 724A-724C
9.
Scherpereel A et al. ERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma. Eur Respir J. 2020;55(6):1900953
10.
NCCN Guidelines®. Malignant Pleural Mesothelioma, Version 1.2022; www.nccn.org/guidelines/guidelines abgerufen am 4. Juli 2022
11.
Woolhouse I et al. BTS guideline for the investigation and management of malignant pleural mesothelioma. BMJ Open Respir Res. 2018;5(1):e000266
12.
Schumann SO et al. Epidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature. J Thorac Dis. 2021;13(4):2510-23
13.
Aigner C et al. [The Current Therapy of Asbestos-Associated Malignant Pleural Mesothelioma - An Expert Consensus Paper]. Pneumologie. 2021;75(10):776-94
14.
Carbone M et al. Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69(5):402-29
15.
Sugarbaker DJ et al. Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy. Eur J Cardiothorac Surg. 2011;40(2):298-303
16.
Kindler HL et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(13):1343-73
17.
Tossavainen A. Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health. 1997;23(4):311-6
18.
National Toxicology Program, Department of Health and Human Services. Report on Carcinogens, Fifteenth Edition, Asbestos, CAS No. 1332-21-4; https://​ntp.​niehs.​nih.​gov/​ntp/​roc/​content/​profiles/​asbestos.​pdf abgerufen am 4. Juli 2022
19.
Pairon JC et al. Pleural plaques and the risk of pleural mesothelioma. J Natl Cancer. Inst 2013; 105(4):293-301
20.
Maxim LD et al. Are pleural plaques an appropriate endpoint for risk analyses? Inhal Toxicol. 2015;27(7):321-34
21.
Ameille J et al. Asbestos-related cancer risk in patients with asbestosis or pleural plaques. Rev Mal Respir. 2011;28(6):e11-17
22.
Kirkham TL et al. Surveillance of mesothelioma and workers' compensation in British Columbia, Canada. Occup Environ Med. 2011;68(1):30-5
23.
Chamming's S et al. Compensation of pleural mesothelioma in France: data from the French National Mesothelioma Surveillance Programme. Am J Ind Med. 2013;56(2):146-54
24.
García-Gómez M et al. Asbestos-related occupational cancers compensated under the Spanish National Insurance System, 1978-2011. Int J Occup Environ Health. 2015; 21(1):31-9
25.
Marinaccio A et al. Pleural malignant mesothelioma epidemic: incidence, modalities of asbestos exposure and occupations involved from the Italian National Register. Int J Cancer. 2012;130(9):2146-54
26.
Park EK et al. Global magnitude of reported and unreported mesothelioma. Environ Health Perspect. 2011;119(4):514-8
27.
Stayner L et al. The Worldwide Pandemic of Asbestos-Related Diseases. Annu Rev Public Health. 2013;34:205-16
28.
Peto J et al. The European mesothelioma epidemic. Br J Cancer. 1999;79(3-4):666-72
29.
Vivero M et al. Clinicopathologic and genetic characteristics of young patients with pleural diffuse malignant mesothelioma. Mod Pathol. 2018;31(1):122-31
30.
Cavazza A et al. Post-irradiation malignant mesothelioma. Cancer. 1996;77(7):1379-85
31.
Teta MJ et al. Therapeutic radiation for lymphoma: risk of malignant mesothelioma. Cancer. 2007;109(7):1432-8
32.
Chirieac LR et al. Clinicopathologic characteristics of malignant mesotheliomas arising in patients with a history of radiation for Hodgkin and non-Hodgkin lymphoma. J Clin Oncol. 2013;31(36):4544-9
33.
Witherby SM et al. Malignant mesothelioma following thoracic radiotherapy for lung cancer. Lung Cancer. 2007;57(3):410-3
34.
Peterson JT Jr et al. Non-asbestos-related malignant mesothelioma. A review. Cancer. 1984; 54(5):951-60.
35.
Farioli A et al. Radiation-induced mesothelioma among long-term solid cancer survivors: a longitudinal analysis of SEER database. Cancer Med. 2016;5(5):950-9
36.
Carbone M et al. Consensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol. 2016;11(8):1246-62
37.
Righi L et al. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study. J Thorac Oncol. 2016;11(11):2006-17
38.
Baumann F et al. Mesothelioma patients with germline BAP1 mutations have 7-fold improved long-term survival. Carcinogenesis. 2015;36(1):76-81
39.
Carbone M et al. BAP1 and cancer. Nat Rev Cancer. 2013;13(3):153-9
40.
American Cancer Society. Cancer Facts & Figures. 2017. Special Section - Rare Cancers in Adults; https://​tinyurl.​com/​yb4joe3c abgerufen am 4. Juli 2022
41.
Musk AW et al. Predicting survival in malignant mesothelioma. Eur Respir J. 2011;38(6):1420-4
42.
Meyerhoff RR et al. Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. J Surg Res. 2015;196(1):23-32
43.
Linton A et al. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer. 2014;111(9):1860-9
44.
Mazurek JM et al. Malignant Mesothelioma Mortality - United States, 1999-2015. MMWR Morb Mortal Wkly Rep. 2017;66(8):214-8
45.
van Meerbeeck JP et al. Malignant pleural mesothelioma: the standard of care and challenges for future management. Crit Rev Oncol Hematol. 2011;78(2):92-111
46.
Jaklitsch MT et al. Treatment of malignant mesothelioma. World J Surg. 2001;25(2):210-7
47.
Husain AN et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2018;142(1):89-108
48.
Marchevsky AM et al. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. Hum Pathol. 2017;67:160-8
49.
Arif Q, Husain AN. Malignant Mesothelioma Diagnosis. Arch Pathol Lab Med. 2015;139(8):978-80
50.
Wang ZJ et al. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics. 2004;24(1):105-19
51.
Paintal A et al. The diagnosis of malignant mesothelioma in effusion cytology: a reappraisal and results of a multi-institution survey. Cancer Cytopathol. 2013;121(12):703-7
52.
Hjerpe A et al. Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. Acta Cytol. 2015;59(1):2-16
53.
Ray M, Kindler HL. Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest. 2009;136(3):888-96
54.
Henderson DW et al. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol. 2013;66(10):847-53
55.
Alì G et al. The pathological and molecular diagnosis of malignant pleural mesothelioma: a literature review. J Thorac Dis. 2018;10(Suppl_2):S276-s284
56.
Nicholson AG et al. EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. J Thorac Oncol. 2020;15(1):29-49
57.
Zhang YZ et al. Utility of Nuclear Grading System in Epithelioid Malignant Pleural Mesothelioma in Biopsy-heavy Setting: An External Validation Study of 563 Cases. 2020;44(3):347-56
58.
Bhatnagar R et al. Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion. N Engl J Med. 2018;378(14):1313-22
59.
Feller-Kopman D, Light R. Pleural Disease. N Engl J Med. 2018;378(18):1754
60.
Zahid I et al. What is the best treatment for malignant pleural effusions? Interact Cardiovasc Thorac Surg. 2011;12(5):818-23
61.
Schneider T et al. Recurrent pleural effusion: who benefits from a tunneled pleural catheter? Thorac Cardiovasc Surg. 2009;57(1):42-6
62.
Roberts HC et al. Screening for malignant pleural mesothelioma and lung cancer in individuals with a history of asbestos exposure. J Thorac Oncol. 2009;4(5):620-8
63.
van Meerbeeck JP, Hillerdal G. Screening for mesothelioma: more harm than good? Am J Respir Crit Care Med. 2008;178(8):781-2
64.
Johnen G et al. Calretinin as a blood-based biomarker for mesothelioma. BMC Cancer. 2017;17(1):386
65.
Pass HI, Carbone M. Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21(2):97-104
66.
Casjens S et al. Assessment of potential predictors of calretinin and mesothelin to improve the diagnostic performance to detect malignant mesothelioma: results from a population-based cohort study. BMJ Open. 2017;7(10):e017104
67.
Felten MK et al. Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers. Int Arch Occup Environ Health. 2014;87(2):195-204
68.
Marchevsky AM et al. Localized malignant mesothelioma, an unusual and poorly characterized neoplasm of serosal origin: best current evidence from the literature and the International Mesothelioma Panel. Mod Pathol. 2020;33(2):281-96
69.
Chirieac LR et al. Diagnostic value of biopsy sampling in predicting histology in patients with diffuse malignant pleural mesothelioma. Cancer. 2019;125(23):4164-71
70.
Pilling J et al. Integrated positron emission tomography-computed tomography does not accurately stage intrathoracic disease of patients undergoing trimodality therapy for malignant pleural mesothelioma. Thorac Cardiovasc Surg. 2010;58(4):215-9
71.
Ahmadzadehfar H et al. False positive 18F-FDG-PET/CT in a patient after talc pleurodesis. Lung Cancer. 2007;58(3):418-21
72.
Nguyen NC et al. F-18 FDG PET/CT characterization of talc pleurodesis-induced pleural changes over time: a retrospective study. Clin Nucl Med. 2009;34(12):886-90
73.
Berzenji L et al. The eighth TNM classification for malignant pleural mesothelioma. Transl Lung Cancer Res. 2018;7(5):543-9
74.
Nowak AK et al. The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma. J Thorac Oncol. 2016;11(12):2089-99
75.
Rusch VW et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012;7(11):1631-9
76.
Pass HI et al. Supplementary prognostic variables for pleural mesothelioma: a report from the IASLC staging committee. J Thorac Oncol. 2014;9(6):856-64
77.
Brims FJ et al. A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis. J Thorac Oncol. 2016;11(4):573-82
78.
Opitz I et al. A New Prognostic Score Supporting Treatment Allocation for Multimodality Therapy for Malignant Pleural Mesothelioma: A Review of 12 Years' Experience. J Thorac Oncol. 2015;10(11):1634-41
79.
de Perrot M et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(9):1413-8
80.
Rusch VW et al. A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma. Ann Thorac Surg. 2016;102(4):1059-66
81.
Herndon JE et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113(3):723-31
82.
Curran D et al. Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16(1):145-52
83.
Garon EB et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28
84.
Popat S et al. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial. Ann Oncol. 2020;31(12):1734-45
85.
Krug LM et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol. 2009;27(18):3007-13
86.
Thieke C et al. Long-term results in malignant pleural mesothelioma treated with neoadjuvant chemotherapy, extrapleural pneumonectomy and intensity-modulated radiotherapy. Radiat Oncol. 2015;10:267
87.
Abdel-Rahman O et al. Radical multimodality therapy for malignant pleural mesothelioma. Cochrane Database Syst Rev. 2018;1(1):Cd012605
88.
De Bondt C et al. Combined modality treatment in mesothelioma: a systemic literature review with treatment recommendations. Transl Lung Cancer Res. 2018;7(5):562-73
89.
Bueno R, Opitz I. Surgery in Malignant Pleural Mesothelioma. J Thorac Oncol. 2018;13(11):1638-54
90.
Bölükbas S et al. Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: the outcome of incomplete resections. Lung Cancer. 2013; 81(2):241-6
91.
Rusch V et al. The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass. J Thorac Cardiovasc Surg. 2013;145(4):909-10
92.
Treasure T et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12(8):763-72
93.
Flores RM et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135(3):620-6, 626.e621-623
94.
Cao C et al. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83(2):240-5
95.
Spaggiari L et al. Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study. Ann Thorac Surg. 2014;97(6):1859-65
96.
Hasani A et al. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia. J Thorac Oncol. 2009; 4(8):1010-6
97.
Bölükbas S et al. Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy. Lung Cancer. 2011;71(1):75-81
98.
Gupta V et al. Patterns of local and nodal failure in malignant pleural mesothelioma after extrapleural pneumonectomy and photon-electron radiotherapy. J Thorac Oncol. 2009;4(6): 746-50
99.
Flores RM et al. Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population. J Thorac Oncol. 2010;5(10):1649-54
100.
Baldini EH et al. Patterns of failure after trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg. 1997;63(2):334-8
101.
Taioli E et al. Meta-analysis of survival after pleurectomy decortication versus extrapleural pneumonectomy in mesothelioma. Ann Thorac Surg. 2015;99(2):472-80
102.
Magouliotis DE et al. Updated meta-analysis of survival after extrapleural pneumonectomy versus pleurectomy/decortication in mesothelioma. Gen Thorac Cardiovasc Surg. 2019;67(3):312-20
103.
Schipper PH et al. Malignant pleural mesothelioma: surgical management in 285 patients. Ann Thorac Surg. 2008;85(1):257-64; discussion 264
104.
Nakas A et al. Long-term survival after lung-sparing total pleurectomy for locally advanced (International Mesothelioma Interest Group Stage T3-T4) non-sarcomatoid malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2012;41(5):1031-6
105.
Schwartz RM et al. Systematic review of quality of life following pleurectomy decortication and extrapleural pneumonectomy for malignant pleural mesothelioma. BMC Cancer. 2018;18(1):1188
106.
Yan TD et al. Extrapleural pneumonectomy for malignant pleural mesothelioma: outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg. 2009;138(3):619-24
107.
Sugarbaker DJ et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg. 2004; 128(1):138-46
108.
Lauk O et al. Extrapleural pneumonectomy after induction chemotherapy: perioperative outcome in 251 mesothelioma patients from three high-volume institutions. Ann Thorac Surg. 2014;98(5):1748-54
109.
Bovolato P et al. Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol. 2014;9(3):390-6
110.
Kucukoner M et al. Clinical characteristics, treatment and survival outcomes in malignant pleural mesothelioma: an institutional experience in Turkey. J BUON 2014;19(1): 164-70
111.
Sugarbaker DJ et al. Extrapleural pneumonectomy in the treatment of epithelioid malignant pleural mesothelioma: novel prognostic implications of combined N1 and N2 nodal involvement based on experience in 529 patients. Ann Surg. 2014;260(4):577-80; discussion 580-2
112.
Saddoughi SA et al. National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study. Ann Thorac Surg. 2018;105(2):432-7
113.
Rosskamp M et al. Real-life treatment practice for malignant pleural mesothelioma in Belgium. Lung Cancer. 2018;125:258-64
114.
Nelson DB et al. Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis. J Clin Oncol. 2017;35(29):3354-62
115.
Beebe-Dimmer JL et al. Mesothelioma in the United States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare investigation of treatment patterns and overall survival. Clin Epidemiol. 2016;8:743-50
116.
Zhao ZY et al. Effect of hyperthermic intrathoracic chemotherapy on the malignant pleural mesothelioma: a systematic review and meta-analysis. Oncotarget. 2017;8(59):100640-7
117.
de Bree E et al. Cytoreductive surgery and intraoperative hyperthermic intrathoracic chemotherapy in patients with malignant pleural mesothelioma or pleural metastases of thymoma. Chest. 2002;121(2):480-7
118.
Lang-Lazdunski L et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: a 10-year experience. J Thorac Cardiovasc Surg. 2015;149(2):558-65; discussion 565-6
119.
Sugarbaker DJ et al. Hyperthermic intraoperative pleural cisplatin chemotherapy extends interval to recurrence and survival among low-risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg. 2013;145(4):955-63
120.
Ried M et al. Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion for malignant pleural tumours: perioperative management and clinical experience. Eur J Cardiothorac Surg. 2013;43(4):801-7
121.
Lang-Lazdunski L et al. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine followed by adjuvant chemotherapy in patients with malignant pleural mesothelioma. J Thorac Oncol. 2011;6(10):1746-52
122.
Boyer MJ et al. O-56 Symptom and quality of life advantages for pemetrexed + cisplatin versus cisplatin in treatment of malignant pleural mesothelioma. Lung Cancer. 2003;41(Suppl_2):S19
123.
Vogelzang NJ et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21(14):2636-44
124.
van Meerbeeck JP et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol. 2005;23(28):6881-9
125.
Bottomley A et al. Short-term treatment-related symptoms and quality of life: results from an international randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an EORTC Lung-Cancer Group and National Cancer Institute, Canada, Intergroup Study. J Clin Oncol. 2006;24(9):1435-42
126.
Byrne MJ et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol. 1999;17(1):25-30
127.
Nowak AK et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer. 2002;87(5):491-6
128.
van Haarst JM et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer. 2002;86(3):342-5
129.
Arrieta O et al. A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma. Cancer Chemother Pharmacol. 2014;73(5):975-82
130.
Zalcman G et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387(10026):1405-14
131.
Srour SA, Stoner JA. Pemetrexed in combination with cisplatin versus carboplatin as first-line therapy in patients with advanced-stage malignant pleural mesothelioma (MPM): A systematic review and meta-analysis. J Clin Oncol. 2016;34(15_suppl):8554-4
132.
Ceresoli GL et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol. 2006;24(9):1443-8
133.
Santoro A et al. Pemetrexed plus cisplatin or pemetrexed plus carboplatin for chemonaïve patients with malignant pleural mesothelioma: results of the International Expanded Access Program. J Thorac Oncol. 2008;3(7):756-63
134.
Katirtzoglou N et al. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin Lung Cancer. 2010;11(1):30-5
135.
Castagneto B et al. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM). Ann Oncol. 2008;19(2):370-3
136.
Ceresoli GL et al. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer. 2013;109(3):552-8
137.
Scagliotti GV et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol. 2003;21(8):1556-61
138.
Taylor P et al. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program. J Thorac Oncol. 2008;3(7):764-71
139.
Muers MF et al. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008;371(9625):1685-94
140.
Baas P et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397(10272):375-86
141.
Peters S et al. LBA65 First-line nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with unresectable malignant pleural mesothelioma (MPM): 3-year update from CheckMate 743. Ann Oncol. 2021;32(Suppl_5):S1341-S1342
142.
Nishino M et al. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2016;2(12):1607-16
143.
Naidoo J et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. J Clin Oncol. 2017;35(7):709-17
144.
Sgambato A et al. Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management. Curr Drug Saf. 2016;11(1):62-8
145.
Shah R et al. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol. Clin Lung Cancer. 2021;22(2):142-6
146.
de Gooijer CJ et al. Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial. Lancet Respir Med. 2021;9(6):585-92
147.
Fennell DA et al. Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND—A Double-Blind, Randomized, Phase II Study. J Clin Oncol. 2019;37(10):790-8
148.
Thomas A, Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol. 2012;13(7):e301-310
149.
Abdel-Rahman O, Kelany M. Systemic therapy options for malignant pleural mesothelioma beyond first-line therapy: a systematic review. Expert Rev Respir Med. 2015;9(5):533-49
150.
Zauderer MG, Krug LM. Novel therapies in phase II and III trials for malignant pleural mesothelioma. J Natl Compr Canc Netw. 2012;10(1):42-7
151.
Ceresoli GL et al. Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev. 2010;36(1):24-32
152.
Bearz A et al. Re-challenge with pemetrexed in advanced mesothelioma: a multi-institutional experience. BMC Res Notes. 2012;5:482
153.
Zucali PA et al. Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer. 2012;75(3):360-7
154.
Ceresoli GL et al. Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma. Lung Cancer. 2011;72(1):73-7
155.
Petrelli F et al. A systematic review and meta-analysis of second-line therapies for treatment of mesothelioma. Respir Med. 2018;141:72-80
156.
Fennell DA et al. A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma. J Clin Oncol. 2021;39(15_suppl):8507-8507
157.
Zucali PA et al. Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. Lung Cancer 2014; 84(3):265-70
158.
Stebbing J et al. The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma. Lung Cancer. 2009; 63(1):94-7
159.
Steele JP et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol. 2000;18(23):3912-7
160.
Manegold C et al. Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol. 2005;16(6):923-7
161.
van Meerbeeck JP et al. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer. 1999;85(12):2577-82
162.
Maio M et al. Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017;18(9):1261-73
163.
Alley EW et al. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. Lancet Oncol. 2017;18(5):623-30
164.
Hassan R et al. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial. JAMA Oncol. 2019;5(3):351-7
165.
Desai A et al. Phase II trial of pembrolizumab (P) in patients (pts) with previously-treated mesothelioma (MM). J Clin Oncol. 2018;36(15_suppl):8565-65
166.
Quispel-Janssen J et al. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma. J Thorac Oncol. 2018;13(10):1569-76
167.
Okada M et al. Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT). Clin Cancer Res. 2019;25(18):5485-92
168.
Scherpereel A et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. Lancet Oncol. 2019;20(2):239-53
169.
Disselhorst MJ et al. Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial. Lancet Respir Med. 2019;7(3):260-70
170.
Calabrò L et al. Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. Lancet Respir Med. 2018;6(6):451-60
171.
Pagano M et al. Randomized phase II study on gemcitabine with or without ramucirumab as second-line treatment for advanced malignant pleural mesothelioma (MPM): Results of Italian Rames Study. J Clin Oncol. 2020;38(15_suppl):9004-4
172.
Fennell DA et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021;22(11):1530-40
173.
Ashton M et al. The role of radical radiotherapy in the management of malignant pleural mesothelioma: A systematic review. Radiother Oncol. 2017;125(1):1-12
174.
Baldini EH. Radiation therapy options for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg. 2009;21(2):159-63
175.
Gupta V et al. Hemithoracic radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2005;63(4):1045-52
176.
Krayenbuehl J et al. Combined photon and electron three-dimensional conformal versus intensity-modulated radiotherapy with integrated boost for adjuvant treatment of malignant pleural mesothelioma after pleuropneumonectomy. Int J Radiat Oncol Biol Phys. 2007;69(5):1593-9
177.
Rimner A, Rosenzweig KE. Novel radiation therapy approaches in malignant pleural mesothelioma. Ann Cardiothorac Surg. 2012;1(4):457-61
178.
Patel PR et al. Effect of increasing experience on dosimetric and clinical outcomes in the management of malignant pleural mesothelioma with intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2012;83(1):362-8
179.
Rimner A et al. Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. J Clin Oncol. 2016;34(23):2761-8
180.
Rice DC et al. Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007;84(5):1685-92; discussion 1692-83
181.
Allen AM et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys. 2006;65(3):640-5
182.
Rosenzweig KE et al. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2012;83(4):1278-83
183.
Yorke ED et al. Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. Int J Radiat Oncol Biol Phys. 2017;99(1):61-9
184.
Rusch VW et al. A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2001;122(4):788-95
185.
Yajnik S et al. Hemithoracic radiation after extrapleural pneumonectomy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2003;56(5):1319-26
186.
Boutin C et al. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest. 1995;108(3):754-8
187.
Trovo M et al. Radical Hemithoracic Radiotherapy Versus Palliative Radiotherapy in Non-metastatic Malignant Pleural Mesothelioma: Results from a Phase 3 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2021;109(5):1368-76
188.
Minatel E et al. OC-0500 Radical Hemi-thoracic Radiotherapy vs. Palliative Radiotherapy for Malignant Pleural Mesothelioma. Radiother Oncol. 2019;133(Suppl_1):S257
189.
Minatel E et al. Radical Radiation Therapy After Lung-Sparing Surgery for Malignant Pleural Mesothelioma: Survival, Pattern of Failure, and Prognostic Factors. Int J Radiat Oncol Biol Phys. 2015;93(3):606-13
190.
Stahel RA et al. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol. 2015;16(16):1651-8
191.
de Graaf-Strukowska L et al. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura--a single-institution experience with 189 patients. Int J Radiat Oncol Biol Phys. 1999;43(3):511-6
192.
Di Salvo M et al. Prevention of malignant seeding at drain sites after invasive procedures (surgery and/or thoracoscopy) by hypofractionated radiotherapy in patients with pleural mesothelioma. Acta Oncol. 2008;47(6):1094-8
193.
Clive AO et al. Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncol. 2016;17(8):1094-1104
194.
Stewart SA et al. Evaluating quality of life and cost implications of prophylactic radiotherapy in mesothelioma: Health economic analysis of the SMART trial. PLoS One 2018;13(2):e0190257
195.
Bayman N et al. Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma: An Open-Label, Multicenter, Phase III Randomized Trial. J Clin Oncol. 2019;37(14):1200-8
196.
Bydder S et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer. 2004;91(1):9-10
197.
O'Rourke N et al. A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma. Radiother Oncol. 2007;84(1):18-22
198.
Davies HE et al. Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues. Curr Opin Pulm Med. 2008;14(4):326-30
199.
MacLeod N et al. Is Radiotherapy Useful for Treating Pain in Mesothelioma?: A Phase II Trial. J Thorac Oncol. 2015;10(6):944-50
200.
Brims F et al. Early specialist palliative care on quality of life for malignant pleural mesothelioma: a randomised controlled trial. Thorax. 2019;74(4):354-61
201.
Freeman RK et al. A Propensity-Matched Comparison of Pleurodesis or Tunneled Pleural Catheter for Heart Failure Patients With Recurrent Pleural Effusion. Ann Thorac Surg. 2014;97(6):1872-7
202.
Muruganandan S et al. Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial. Lancet Respir Med. 2018;6(9):671-80
203.
Matthews C et al. MesoTRAP: a feasibility study that includes a pilot clinical trial comparing video-assisted thoracoscopic partial pleurectomy decortication with indwelling pleural catheter in patients with trapped lung due to malignant pleural mesothelioma designed to address recruitment and randomisation uncertainties and sample size requirements for a phase III trial. BMJ Open Respir Res. 2019;6(1):e000368
204.
Rintoul RC et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014;384(9948):1118-27
205.
Thapa B et al. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma. J Thorac Oncol. 2017;12(5):850-9
206.
Tumeh PC et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568-71
207.
Rizvi NA et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-8
208.
Süveg K et al. Current efforts in research of pleural mesothelioma-An analysis of the ClinicalTrials.gov registry. Lung Cancer. 2018;124:12-8
Metadaten
Titel
Brustfellkrebs
Epidemiologie, Diagnostik und Therapie des Pleuramesothelioms
verfasst von
Dr. med. Dominik Valentin Flury
Prof. Dr. med. Gregor J. Kocher
Publikationsdatum
28.07.2022
Verlag
Springer Medizin
Erschienen in
InFo Hämatologie + Onkologie / Ausgabe 7-8/2022
Print ISSN: 2662-1754
Elektronische ISSN: 2662-1762
DOI
https://doi.org/10.1007/s15004-022-9127-y

Weitere Artikel der Ausgabe 7-8/2022

InFo Hämatologie + Onkologie 7-8/2022 Zur Ausgabe

Neues aus der Forschung

Neues Fusionsprotein macht Hoffnung

Neues aus der Forschung

Antikörper-Konjugat oder CAR-T-Zellen?

Journal club

Primäre Immuntherapie bei mCRC – hohe und klinisch relevante Effektivität

Neues aus der Forschung

So kann die Mandibula erhalten bleiben

Praxis aktuell

Mehrheit weiß nicht, was mit digitalen Patientendaten passiert

Schwerpunkt

Erstlinientherapie bei nicht-intensiv therapierbarer AML

Weitere Lesetipps

ANZEIGE

Im Dialog mit jungen Dermatologen: Wund- und Narbenversorgung in der Praxis

Ethnische Vielfalt in der ästhetischen Praxis berücksichtigen

Krebspatientin unter "Chemo" geht es plötzlich schlechter

ANZEIGE

Erfolgreiche Therapie von hypertrophen Narben und Keloiden

Arbeitsmedizinische Aspekte in der Onkologie: Wonach muss gefragt werden?

ANZEIGE

Weißer Hautkrebs verursacht mehr Tote als das Melanom

Bildnachweise